Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies SA (DBVT) is a clinical-stage biopharmaceutical leader advancing epicutaneous immunotherapy (EPIT) through its innovative Viaskin platform, targeting food allergies with non-invasive precision. This page aggregates all essential updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.
Investors and stakeholders gain centralized access to critical developments including phase trial results, FDA/EMA interactions, and partnership announcements. Each update is curated to provide actionable insights into DBVT’s pioneering work in allergy treatment while maintaining rigorous scientific accuracy.
Key coverage areas include Viaskin efficacy data, patent developments, and manufacturing scalability updates. The resource is designed to help users track the company’s progress from clinical research to potential commercialization without requiring cross-platform monitoring.
Bookmark this page for streamlined tracking of DBV Technologies’ advancements in redefining food allergy management through its unique skin-based immunotherapy approach.
DBV Technologies will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 17, 2022, at 10:00 a.m. ET. Dr. Pharis Mohideen, the Chief Medical Officer, is set to deliver the presentation. Investors can access the webcast on the company's website, with a replay available for about 90 days post-event. DBV Technologies focuses on developing Viaskin™, an innovative technology platform for immunotherapy, particularly aimed at food allergies, with ongoing trials for Viaskin Peanut.
DBVT announced its monthly update as of February 28, 2022, regarding the total number of shares and voting rights. The company reported a total of 55,095,762 shares, with a total gross of 55,095,762 voting rights. After accounting for shares without voting rights, the total net voting rights stood at 54,919,952. This information is in compliance with the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies announced the filing of its 2021 Annual Report on Form 10-K with the SEC and its 2021 Universal Registration Document with the French AMF. Both documents are accessible on the company's investor website and the respective regulatory authority sites. DBV Technologies is focused on developing the Viaskin™ platform for food allergies using epicutaneous immunotherapy, with ongoing trials for Viaskin Peanut. The company operates globally from Montrouge, France, and Summit, NJ, and its shares are listed on Euronext and Nasdaq under the ticker DBVT.
DBV Technologies reported its 2021 financial results, revealing a net loss of $97.8 million, down from $159.6 million in 2020. The company's cash and cash equivalents decreased to $77.3 million from $196.4 million in 2020. Operating income fell to $5.7 million, primarily due to reduced revenue from a collaboration with Nestlé. However, DBV extended its cash runway into Q1 2023 through cost containment measures. The pivotal protocol for the modified Viaskin Peanut patch is complete and ready for FDA submission, highlighting ongoing discussions with the FDA aimed at advancing its research and development efforts.
DBV Technologies will report its full year 2021 financial results on March 3, 2022. The company, based in Montrouge, France, is focused on developing the Viaskin platform for immunotherapy, specifically for food allergies. A conference call will be held at 5:00 p.m. ET to discuss the financial outcomes and provide corporate updates. The call can be accessed via specified teleconferencing numbers and a live audio webcast will be available on their website.
DBV Technologies (DBVT) will participate in the AAAAI 2022 Congress from February 24-28, 2022. They will present two scientific posters: one on allergy specialty care effects on healthcare utilization in children with peanut allergies and another on pooled safety data from Phase 3 trials of their Viaskin Peanut treatment. Viaskin Peanut aims to reduce allergic reactions in children aged 4-11. The presentations will be available on-demand for registered attendees and later on DBV's website.
DBV Technologies announced that CEO Daniel Tassé will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18 at 8:40 am ET. This event will be hosted in a virtual format, allowing interested parties to access the webcast through the Investors & Media section of the Company’s website. A replay will be available after the event.
DBV Technologies, based in Montrouge, France, focuses on developing Viaskin™, a proprietary technology for food allergy treatment. The Company's shares trade under the ticker DBVT on Nasdaq.
DBVT released its monthly report on voting rights and share count as of January 31, 2022. The total number of shares stood at 55,095,762, with the total gross of voting rights also at 55,095,762. The net voting rights, after accounting for shares without voting rights, totaled 54,925,155. This information ensures transparency for investors and complies with regulations set by the Autorité des Marchés Financiers.
DBV Technologies has published its Half-Year Report on the liquidity contract with ODDO BHF as of December 31, 2021.
The liquidity account contained 153,631 shares worth €175,542.33, compared to 24,313 shares and €682,454.94 at the contract's inception in July 2018. In 2021's second half, 1,206 shares were purchased and 1,065 sold, totaling 455,657 shares bought for €3,256,011.54 and 379,901 sold for €2,951,075.39. DBV is advancing Viaskin™, a non-invasive immunotherapy platform targeting food allergies.
DBVT announced its monthly update on voting rights and total shares as of December 31, 2021. The total number of shares outstanding is 55,095,762, while the total gross of voting rights stands at 55,095,762. After accounting for shares without voting rights, the total net voting rights reach 54,942,131. This information complies with the regulations of the Autorité des Marchés Financiers.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
